Companies · Biotechnology

Cardiac Implants LLC

AMERICAN CANYON · Biotechnology

Diligence memoA one-page analyst read on Cardiac Implants LLC — recommendation, valuation, rhythm, risks.
$13.5M
Total raised · real
1
Rounds
Latest step-up
Top 40%
Sector rank · raised
Series A
Latest stage · inferred · Fri Aug 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Cardiac Implants LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 4.02× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Dormant
  • Last raise 3.9 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Cardiac Implants LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
3.9 yr record
Peak capital year was 2022 with $13.5M across 1 filings.
Market position
ahead of 61% of Biotechnology peers
Capital scale is ahead of 61% of Biotechnology peers; modeled value is above 70% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2022: $13.5M across 1 filings.
  • Largest single filing was $13.5M on 2022-08-05.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Cardiac Implants LLC is one of 4291 Biotechnology companies tracked from AMERICAN CANYON. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
11
Investors (latest)
2022-08-05
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2022-08-05 Raised $14M (real) Modeled valuation $178M (est)$14M$178MSeries A2022

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$13.5M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$178.2M
Base estimate est.
$14.8M
Conservative case
$597.5M
Upside case
$61.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
3.9 yr
Elapsed time used
3.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
3.9 yr
On record since
2022
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.9× above median
This company$13.5M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.5× above median
This company$13.5M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.8× above median
This company$178.2M
Sector median$64.2M

Raised more than 61% of sector peers (real $). Modeled value above 70% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 303.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.0M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $215.9M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $206.8M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.3M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $188.9M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.0M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.7M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $183.8M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.2M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.1M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $168.8M (est)Cardiac Implants LLC (this company) Raised $13.5M · modeled $178.2M (est)Cardiac Implants LLC
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.0M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$215.9M4.87×
Adient Medical, Inc.Series A$18.2M$206.8M4.67×
Entegrion IncSeries A$22.7M$191.3M4.32×
BCD Bioscience, Inc.Series A$16.4M$188.9M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.0M4.20×
MicroByre, Inc.Series A$16.1M$185.7M4.19×
Cardiac Insight, Inc.Series A$38.1M$183.8M4.15×
Cardiac Implants LLC this companySeries A$13.5M$178.2M4.02×
Abintus Bio, Inc.Series A$13.7M$177.2M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.1M3.98×
Mazen Animal Health Inc.Series A$13.5M$168.8M3.81×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$13.5M2022-08-05$61.6M$178.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$13.5M2022-08-05
    • First recorded raise — entered as Series A.
    • 11 investors on this round.
Intelligence
Modeled next raise
$21.7M
Modeled next size est.range $14.1M$34.7M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
James Barry4 other2022-08
Richard Geoffrion2 other2022-08
Mark Turco2022-08
Michael Butscheidt2022-08
Stephen Magowan2022-08
Registry & provenance

Cardiac Implants LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1942375
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CircuLite IncBiotechnologySeries A$22.0M$415.7Mnetwork1 shared operator · same sector · same stage
Mazen Animal Health Inc.BiotechnologySeries A$13.5M$168.8Msame sector · same stage
ONCOSEC MEDICAL IncBiotechnologySeries A$13.6M$205.5Msame sector · same stage
Abintus Bio, Inc.BiotechnologySeries A$13.7M$177.2Msame sector · same stage
X-Biotix Therapeutics, Inc.BiotechnologySeries A$13.4M$145.0Msame sector · same stage
Halscion IncBiotechnologySeries A$13.8M$155.4Msame sector · same stage
Intellicyt CorpBiotechnologySeries A$13.8M$196.8Msame sector · same stage
Arcturus Therapeutics, Inc.BiotechnologySeries A$13.3M$214.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Innovative Cardiovascular Solutions, LLCBiotechnologySeed$13.0M90%
Cardiac Insight, Inc.BiotechnologySeries A$183.8M89%
Native Cardio, Inc.BiotechnologySeed$505K88%
CardioFocus, Inc.BiotechnologySeries B$351.9M88%
Cardio Diagnostics Holdings, Inc.BiotechnologyPre-Seed$5.9M87%
Second Heart Assist, Inc.BiotechnologySeries B$39.7M87%
Cardio Diagnostics Inc.BiotechnologySeries A$94.1M87%
Phoenix Cardiac Devices, Inc.BiotechnologySeries A$179.6M87%
Frequently asked
How much funding has Cardiac Implants LLC raised?
Cardiac Implants LLC has raised approximately $13.5M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Cardiac Implants LLC's estimated valuation?
Provath's modeled valuation for Cardiac Implants LLC is approximately $178.2M (modeled range $14.8M–$597.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cardiac Implants LLC at?
Cardiac Implants LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Aug 05.
What does Cardiac Implants LLC do and where is it based?
Cardiac Implants LLC operates in the Biotechnology sector, based in AMERICAN CANYON.
Explore related

See where Cardiac Implants LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cardiac Implants LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.